Ashfield appoints new regional presidents in US and Japan
Posted: 13 June 2017 | Niamh Marriott (European Pharmaceutical Review) | No comments yet
Ashfield welcomes Greg Flynn to the US and Mick O’Leary to Japan…
Ashfield, part of UDG Healthcare, a global leader in commercialisation services for the pharmaceutical and healthcare industry, have appointed Greg Flynn as Regional President of Ashfield Commercial and Clinical in the US and Mick O’Leary as Regional President of Ashfield Commercial and Clinical in Japan, where he will lead CMIC Ashfield.
Greg Flynn
Greg Flynn will oversee US operations of Commercial, Clinical, Medical Information, Pharmacovigilance and Market Access. Greg is transitioning to this role from his prior position as Regional President in Japan and Representative Director of CMIC Ashfield, a joint initiative between CMIC Holdings and UDG Healthcare. Under Greg’s leadership, Ashfield became an industry leading partner with over 650 staff across 44 clients in five years.
Commenting on his appointment, Greg Flynn said:
“Through the talent of our people and Ashfield’s commitment to helping improve lives, I have seen the power of what we do in this organisation. The US business has experienced phenomenal growth in the last two years and this new role is an exciting opportunity to continue that growth. I am excited about the future of Ashfield in the US and being part of the next phase in this company’s journey.”
Mick O’Leary
Mick O’LearyMick O’Leary will take over the role as Regional President in Japan, leading the CMIC Ashfield joint venture. Mick was previously the Managing Director for Ashfield Ireland, and has over 20 years’ experience in the pharmaceutical sales industry. Under Mick’s leadership, Ashfield has been established as the Number 1 CSO in Ireland with over 60% market share.
Mick O’Leary commented:
“I am delighted to accept the role of Regional President in Japan and support the group’s overall strategy of expansion in growth markets. CMIC Ashfield is a winning proposition, combining the experience and expertise of a leading international CSO, with the local knowledge and capability of one of Japan’s leading CSOs. We’ll continue to excel by providing flexible, evidence-based services and I look forward to working with new clients and brand challenges in Japan.”
Julian Tompkins, Global President for Ashfield Clinical and Commercial business also commented: “With Greg’s innovative thinking and focus on people, we are looking forward to seeing his impact on the U.S. business. The appointment of Mick O’Leary as Regional President in Japan will continue our success story and excellent results in the second largest global pharmaceutical market. He has exactly the right expertise and drive to lead CMIC Ashfield and continue our strong progress in Japan.”
“We are delighted to have appointed these critical roles for the business. Greg’s leadership in the Japanese market has yielded remarkable growth and proven his dedication to Ashfield’s success.”
